Ludwig & Agenus to Advance Three Checkpoint Modulator Antibodies

March 5, 2014 Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development. These product candidates—two GITR agonists and a CTLA-4 antagonist—target cell-surface checkpoint proteins that control immune responses. They are part of Agenus’ recent acquisition of 4-Antibody AG and the result of several years of intensive collaborative efforts …

Genocea Biosciences Announces Collaboration to Characterize T Cell Responses to Cancer Antigens

March 3, 2014 Genocea Biosciences, Inc., a company pioneering novel T cell vaccines and immunotherapies, today announced a joint research collaboration with Dana-Farber Cancer Institute and Harvard Medical School to characterize anti-tumor T cell responses in melanoma patients. This collaboration extends the use of the company’s proprietary ATLAS™ platform for the rapid discovery of T cell antigens to cancer immunotherapy approaches. “ATLAS™ has proven …

iTeos Therapeutics SA Files Patent for Immunomodulators in Cancer Immunotherapy

February 10th, 2014 iTeos Therapeutics SA today announced the filing of the Company’s first patent applications protecting proprietary inhibitors of the intracellular enzyme TDO2, which is expressed at high levels in specific cancers. iTeos Therapeutics has collaborated with Ludwig Cancer Research over the last year to identify small molecule inhibitors of the enzyme that display nanomolar potency, good selectivity, favorable …

Personalized ovarian cancer vaccine trial results look promising

A new ovarian cancer vaccine has shown promise in clinical trials. The cancer vaccine relies on an innovative two-step immunotherapy approach, the first step of which is to manufacture a personalized dendritic cell vaccine by exposing the patient's dendritic cells to tumour tissue collected during surgery. The primed dendritic cells are then sent back into the body to raise the …

CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine

Triggered by ongoing and very successful multi-year collaboration June 1, 2014 CureVac, a German clinical-stage biopharmaceutical company, today announced the execution of an exclusive license agreement with Sanofi Pasteur S.A., the vaccines division of Sanofi , to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen. In 2011, CureVac and Sanofi Pasteur signed a collaboration and license option agreement …

Celldex’s Phase 1 Study of CDX-1401 Published in Science Translational Medicine

First clinical study to demonstrate that an off-the-shelf vaccine targeting dendritic cells can safely lead to robust humoral and cellular immunity April 16, 2014 Celldex Therapeutics, Inc. announced today that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine (Vol 6 Issue 232). The data demonstrate robust antibody …